FDA approves tablet form of Evrysdi for spinal muscular atrophy
The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...
The American Journal of Managed Care23h
Phase 1 Study Identifies Casdatifan Dose With Promising Responses in Pretreated Clear Cell RCC
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory mechanisms, empowering genes that promote tumor growth in clear cell renal cell ...